Stoke Therapeutics Inc. presented updates on its pipeline of RNA-based medicines targeting diseases caused by protein insufficiency. The company highlighted progress in its lead program, zorevunersen, for Dravet syndrome, noting that Phase 3 enrollment is underway with completion expected in the second quarter of 2026 and a data readout anticipated in mid-2027 to support a potential NDA filing. Additional updates included the initiation of a Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the UK and Europe, and ongoing lead optimization to identify a clinical candidate for SYNGAP1-related disorders in 2026. Stoke reported a strong balance sheet with approximately $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and outlined continued investment in research and platform expansion. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.